Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (1-10 of 172) with videos related to

Pageof 18
Sort By:
Immunity|August 17, 2017
Making It Personal: Neoantigen Vaccines in Metastatic MelanomaMatthew D Hellmann, Alexandra Snyder
Nature Medicine|February 8, 2019
Adding to the checkpoint blockade armamentariumMatthew D Hellmann, Alexandra Snyder
Nature|July 17, 2020
An umbrella approach to test lung cancer therapiesAlexander Drilon, Matthew D Hellmann
The New England Journal of Medicine|March 22, 2018
Adverse Events Associated with Immune Checkpoint BlockadeMichael A Postow, Matthew D Hellmann
Cancer Cell|April 15, 2020
Acquired Resistance to Immune Checkpoint InhibitorsAdam J Schoenfeld, Matthew D Hellmann
The New England Journal of Medicine|February 27, 2020
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. ReplyMatthew D Hellmann, Suresh S Ramalingam
Cancer Journal (Sudbury, Mass.)|January 24, 2018
PD-1/PD-L1 Axis in Lung CancerFernando C Santini, Matthew D Hellmann
The New England Journal of Medicine|September 13, 2018
Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Luis Paz-Ares
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
First-Line Immunotherapy for Non-Small-Cell Lung CancerMartin Reck, Jordi Remon, Matthew D Hellmann
The New England Journal of Medicine|January 11, 2018
Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeMichael A Postow, Robert Sidlow, Matthew D Hellmann
Pageof 18

Showing results (1-10 of 172) with videos related to

Sort By:
Pageof 18
Immunity|August 17, 2017
Making It Personal: Neoantigen Vaccines in Metastatic MelanomaMatthew D Hellmann, Alexandra Snyder
Nature Medicine|February 8, 2019
Adding to the checkpoint blockade armamentariumMatthew D Hellmann, Alexandra Snyder
Nature|July 17, 2020
An umbrella approach to test lung cancer therapiesAlexander Drilon, Matthew D Hellmann
The New England Journal of Medicine|March 22, 2018
Adverse Events Associated with Immune Checkpoint BlockadeMichael A Postow, Matthew D Hellmann
Cancer Cell|April 15, 2020
Acquired Resistance to Immune Checkpoint InhibitorsAdam J Schoenfeld, Matthew D Hellmann
The New England Journal of Medicine|February 27, 2020
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. ReplyMatthew D Hellmann, Suresh S Ramalingam
Cancer Journal (Sudbury, Mass.)|January 24, 2018
PD-1/PD-L1 Axis in Lung CancerFernando C Santini, Matthew D Hellmann
The New England Journal of Medicine|September 13, 2018
Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Luis Paz-Ares
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
First-Line Immunotherapy for Non-Small-Cell Lung CancerMartin Reck, Jordi Remon, Matthew D Hellmann
The New England Journal of Medicine|January 11, 2018
Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeMichael A Postow, Robert Sidlow, Matthew D Hellmann
Pageof 18